Osteoporosis Treatment After Forteo Intolerance

Introduction to Alternative Therapies

The American College of Physicians recommends switching to oral bisphosphonates, such as alendronate or risedronate, as first-line alternative therapy after discontinuing Forteo due to side effects, to prevent loss of bone gains and reduce fracture risk 1, 2
Patients initially treated with anabolic agents like teriparatide must be offered an antiresorptive agent after discontinuation to preserve gains and prevent serious risk of rebound and multiple vertebral fractures 1, 2

The American College of Physicians recommends prescribing generic oral bisphosphonates, such as alendronate or risedronate, as the preferred alternative due to high-certainty evidence for fracture reduction, excellent safety profile, and significantly lower cost 1, 2, 3
High-certainty evidence supports bisphosphonates as first-line therapy with the most favorable balance of benefits, harms, patient values, and cost 1, 2
Generic formulations are strongly recommended over brand-name medications due to equivalent efficacy at substantially lower cost 1, 2

Denosumab is recommended as second-line therapy with moderate-certainty evidence for postmenopausal women and low-certainty evidence for men 1, 3
Denosumab reduces fragility fractures by 39-40% compared to placebo 4
IV bisphosphonates, such as zoledronic acid, carry a higher risk profile than oral formulations but may be necessary for patients unable to tolerate oral medications 5, 6

All patients require calcium 1000-1200 mg daily and vitamin D 800-1000 IU daily regardless of pharmacologic choice 1, 2, 8, 7
Adequate calcium and vitamin D intake is essential for fracture prevention in all patients with osteoporosis 1, 2

Plan to continue bisphosphonate therapy for 5 years, then reassess fracture risk to determine if treatment continuation is warranted 1, 2
Current evidence suggests stopping bisphosphonates after 5 years unless strong indication for continuation exists, as longer duration increases risk for osteonecrosis of the jaw and atypical femoral fractures 1, 2
Avoid prescribing brand-name bisphosphonates when generic formulations provide equivalent efficacy at substantially lower cost 1, 2